Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 loss |
Therapy | Lisocabtagene maraleucel |
Indication/Tumor Type | chronic lymphocytic leukemia/small lymphocytic lymphoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 loss | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | Lisocabtagene maraleucel | Guideline | Actionable | Breyanzi (lisocabtagene maraleucel) is indicated in guidelines for patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with TP53 loss after prior BTK inhibitor-based and BCL2 inhibitor-containing regimens (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |